JPM26: Sanofi's COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Among these, one that will be keenly watched is Phase III COAST-2 (NCT06181435) data readout for amlitelimab for atopic dermatitis (AD), which, if positive, will pave the way for amlitelimab's regulatory submission as first-in-class OX40-ligand inhibitor and could potentially reinvigorate Sanofi's AD portfolio beyond Dupixent. The purpose of the COAST 1 study (NCT06130566) was to measure the efficacy and safety of treatment with amlitelimab in individuals with moderate-to-severe AD. The primary endpoint was to assess the proportion of participants with Validated Investigator Global Assessment scale for AD (vIGA-AD) of 0 (clear) or 1 (almost clear) after 24 weeks in comparison to individuals administered a placebo. Additionally, secondary outcome measures included the proportion of participants reaching a 75% reduction from baseline in Eczema Area and Severity Index (EASI-75) after 24 weeks in comparison to placebo. In September 2025, Sanofi announced that amlitelimab met all prim
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sanofi (NASDAQ:SNY) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- JPM26: Leo Pharma's growth strategy puts a spotlight on rare dermatology diseases [Yahoo! Finance]Yahoo! Finance
- State Street's crypto push, FDA delays review of Eli Lilly GLP-1 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]Seeking Alpha
SNY
Sec Filings
- 1/16/26 - Form 6-K
- 1/9/26 - Form 6-K
- 12/29/25 - Form 6-K
- SNY's page on the SEC website